KENGREAL (The Medicines Company)


Welcome to the PulseAid listing for the KENGREAL drug offered from The Medicines Company. This P2Y12 Platelet Inhibitor [EPC],Decreased Platelet Aggregation [PE],P2Y12 Receptor Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: The Medicines Company
NON-PROPRIETARY NAME: cangrelor
SUBSTANCE NAME: CANGRELOR
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: P2Y12 Platelet Inhibitor [EPC],Decreased Platelet Aggregation [PE],P2Y12 Receptor Antagonists [MoA]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2015-07-08
END MARKETING DATE: 0000-00-00


KENGREAL HUMAN PRESCRIPTION DRUG Details:

Item DescriptionKENGREAL from The Medicines Company
LABELER NAME: The Medicines Company
DEA SCHEDULE:
ACTIVE STRENGTH: 50(mg/1)
START MARKETING DATE: 2015-07-08
END MARKETING DATE: 0000-00-00
PRODUCT ID: 65293-003_e16d2568-1d43-420c-a2b4-850f85861271
PRODUCT NDC: 65293-003
APPLICATION NUMBER: NDA204958

Other CANGRELOR Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Chiesi USA, Inc.KENGREAL
The Medicines CompanyKENGREAL